Cutaneous T-Cell Lymphoma Drug Pipeline: 18 Assets by Phase

How many cutaneous T-cell lymphoma drugs are in each phase of development?

Douglas Insights counts 1 cutaneous T-cell lymphoma candidates in Phase III, 5.6% of the 18 assets in development; Phase II holds 6 and Phase I holds 11.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each cutaneous T-cell lymphoma asset appears in exactly one row. The 62 trials still recruiting or running carry 38% of the 164 registered trials in scope.

Which approved cutaneous T-cell lymphoma medicines are still in trials?

1 medicines already on the market are still being tested in cutaneous T-cell lymphoma Phase IV trials; Mogamulizumab has the most, with 16 registered trials.

Post-approval cutaneous T-cell lymphoma trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many cutaneous T-cell lymphoma trials are recruiting patients now?

32 cutaneous T-cell lymphoma trials are recruiting patients and 12 more have not started recruiting yet, out of 164 interventional trials in scope; together they make up 27% of the trial base.

Terminated, suspended and withdrawn cutaneous T-cell lymphoma trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the cutaneous T-cell lymphoma pipeline?

Affimed GmbH leads the cutaneous T-cell lymphoma pipeline with 1 candidates; the top 5 sponsors hold 28% of the 18 assets, and 18 sponsors run at least one.

Industry sponsors lead 53 of the 164 cutaneous T-cell lymphoma trials (32%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the cutaneous T-cell lymphoma pipeline?

Mechanism and drug-type classification for the 18 cutaneous T-cell lymphoma candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What cutaneous T-cell lymphoma trial readouts are coming next?

2 cutaneous T-cell lymphoma candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many cutaneous T-cell lymphoma readouts fall in each quarter?

3 cutaneous T-cell lymphoma candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 1, due in Q1 2027.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most cutaneous T-cell lymphoma trials?

United States hosts the most cutaneous T-cell lymphoma trials, with sites in 122 of the 164 studies (74%); trials in scope run in 25 countries in all.

A multinational cutaneous T-cell lymphoma trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are cutaneous T-cell lymphoma drugs being tested?

122 of the 164 cutaneous T-cell lymphoma trials (74%) have a site in the United States, 27 (16%) in Europe and 14 (8.5%) in China; 15 of the 18 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational cutaneous T-cell lymphoma trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the cutaneous T-cell lymphoma pipeline since the last update?

This is the first edition of the cutaneous T-cell lymphoma pipeline count, dated 4 Oct 2026. The next refresh is due by 2 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the cutaneous T-cell lymphoma pipeline?

Douglas Insights read 164 interventional trials registered on ClinicalTrials.gov for the conditions "lymphoma, t-cell, cutaneous", "cutaneous t-cell lymphoma", "mycosis fungoides" and updated since 4 Oct 2021, then grouped every drug or biologic named in them into 18 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the cutaneous T-cell lymphoma pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage